Odyssey Therapeutics, Inc. SEC filings ODTX

Odyssey Therapeutics, Inc. has 72 filings in SEC EDGAR's recent list, going back to Oct 14, 2021. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.

Odyssey Therapeutics, Inc. SEC filings
Form Description Filed Period
8-K Current report
Results of operations
Nov 4, 2026 Nov 4, 2026
8-K Current report
Regulation FD disclosure
Oct 20, 2026 Oct 20, 2026
8-K Current report
Regulation FD disclosure
Sep 9, 2026 Sep 8, 2026
8-K Current report
Results of operations
Aug 4, 2026 Aug 4, 2026
8-K Current report
Regulation FD disclosure
Jun 23, 2026 Jun 23, 2026
8-K Current report
Results of operations
Jun 17, 2026 Jun 17, 2026
8-K Current report
Material agreement, Unregistered share sale, Bylaw or fiscal year change
May 11, 2026 May 7, 2026

Showing 7 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
ODTX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boston, MA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1882782

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.